Itochu Of Japan To Invest In China's Nandacro CRO Services
This article was originally published in PharmAsia News
Executive Summary
Japan's Itochu says its Acronet subsidiary intends to purchase 14 percent of China's Nandacro, which provides services for China-based clinical trials